Tebaa Amina, Benkirane Raja, Alj Loubna, Cherkaoui Imad, Soulaymani-Bencheikh Rachida
Centre Anti Poison et de Pharmacovigilance du Maroc (CAPM), Ministry of Health, Rue Lamfedel Cherkaoui, Rabat Instituts, Madinate Al Irfane, B.P. 6671, Rabat 10100, Morocco.
Ecole Nationale de Santé Publique (ENSP), Ministry of Health, Rabat, Morocco.
Ther Adv Vaccines Immunother. 2022 Mar 29;10:25151355221088157. doi: 10.1177/25151355221088157. eCollection 2022.
A vaccination campaign against pandemic influenza A/H1N1 was implemented in Morocco between November 2009 and April 2010. Overall, 705,883 subjects were vaccinated by , , and . The adverse events following immunization (AEFIs) data comparison was made with the 2014/2015 seasonal influenza vaccination campaign that was specifically investigated.
To evaluate the safety of the 2009 pandemic influenza A/H1N1 vaccine and to compare it to that of 2014 seasonal influenza vaccine.
During the pandemic vaccination campaign, the Morocco Pharmacovigilance Centre reinforced passive AEFI surveillance with an active and prospective monitoring programme of 1000 immunized people over 6 months at 10 randomly selected vaccination centres. For the 2014/2015 seasonal vaccination campaign, AEFI data were collected from spontaneous notifications.
Active monitoring of 2009 pandemic collected 771 AEFI reports, corresponding to an AEFI incidence rate of 77.1% with vaccination by either or vaccine in 95% of cases. Reported AEFI were most frequently local (37.7%), general (29.5%), and neurological reactions (20.3%). Most of the AEFI (95.5%) were observed during the first 48 hours after vaccination, and the remainder within 2 weeks. None of the reported AEFI were serious case. The highest rate of notification was documented for health professionals, followed by patients with diabetes or chronic respiratory diseases. Concerning passive surveillance, the AEFI notification rate was significantly higher for the 2009/2010 pandemic vaccine (3.1 1.2 per 10,000). However, there was no significant difference between pandemic and seasonal vaccination with regards to the serious adverse events (SAE) notification rate (0.3 0.2 per 10,000).
Data analysis indicates that the vaccines used against 2009 pandemic influenza in Morocco have a satisfactory safety profile, similar to the seasonal influenza vaccine with the exception of local reactions as observed previously in other countries.
2009年11月至2010年4月期间,摩洛哥开展了针对甲型H1N1大流行性流感的疫苗接种活动。总体而言,共有705,883名受试者通过[此处原文缺失相关疫苗接种方式信息]进行了疫苗接种。对免疫接种后不良事件(AEFIs)数据进行了比较,与专门调查的2014/2015年季节性流感疫苗接种活动的数据作对比。
评估2009年甲型H1N1大流行性流感疫苗的安全性,并将其与2014年季节性流感疫苗的安全性进行比较。
在大流行性流感疫苗接种活动期间,摩洛哥药物警戒中心通过一项主动前瞻性监测计划加强了对AEFIs的被动监测,该计划在10个随机选择的疫苗接种中心对1000名接种疫苗超过6个月的人进行监测。对于2014/2015年季节性疫苗接种活动,AEFIs数据是从自发报告中收集的。
对2009年大流行性流感疫苗的主动监测收集到771份AEFIs报告,在95%的病例中,使用[此处原文缺失相关疫苗接种方式信息]疫苗接种后的AEFIs发生率为77.1%。报告的AEFIs最常见的是局部反应(37.7%)、全身反应(29.5%)和神经反应(20.3%)。大多数AEFIs(95.5%)在接种疫苗后的头48小时内出现,其余在2周内出现。报告的AEFIs均无严重病例。卫生专业人员的报告率最高,其次是糖尿病或慢性呼吸道疾病患者。关于被动监测,2009/2010年大流行性流感疫苗的AEFIs报告率显著更高(每10,000人中有3.1±1.2例)。然而,在严重不良事件(SAE)报告率方面,大流行性流感疫苗接种和季节性疫苗接种之间没有显著差异(每10,000人中有0.3±0.2例)。
数据分析表明,摩洛哥用于2009年大流行性流感的疫苗具有令人满意的安全性,与季节性流感疫苗相似,但局部反应情况如之前在其他国家所观察到的那样除外。